Moreover, to test if a gene knockout that leads to reduced tumor growth would impact the antitumor effect of the drug combination, we chose to treat ERBB3-KO tumors, which resulted in reduced xenograft tumor growth (21). Here, ERBB3 is linked to neoplasm.